Business Description
Lisata Therapeutics Inc
NAICS : 325414
SIC : 8099
ISIN : US1280582032
Description
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 300.8 | |||||
| Equity-to-Asset | 0.88 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 44.6 | |||||
| 3-Year EPS without NRI Growth Rate | 29 | |||||
| 3-Year FCF Growth Rate | 33.9 | |||||
| 3-Year Book Growth Rate | -38.3 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 36.56 | |||||
| 9-Day RSI | 37.05 | |||||
| 14-Day RSI | 39.29 | |||||
| 6-1 Month Momentum % | 61.53 | |||||
| 12-1 Month Momentum % | 1.84 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.18 | |||||
| Quick Ratio | 8.18 | |||||
| Cash Ratio | 7.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -84.8 | |||||
| Shareholder Yield % | 1.15 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -36.36 | |||||
| ROA % | -33.13 | |||||
| ROIC % | -2071.19 | |||||
| ROC (Joel Greenblatt) % | -10986.32 | |||||
| ROCE % | -44.82 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.45 | |||||
| Price-to-Tangible-Book | 0.45 | |||||
| EV-to-EBIT | 1.04 | |||||
| EV-to-EBITDA | 1.05 | |||||
| EV-to-FCF | 1.34 | |||||
| Price-to-Net-Current-Asset-Value | 0.46 | |||||
| Price-to-Net-Cash | 0.49 | |||||
| Earnings Yield (Greenblatt) % | 96.15 | |||||
| FCF Yield % | -90.66 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers